Related Experiment Video
Updated: Jan 24, 2026

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
Clinically-approved CFTR modulators rescue Nrf2 dysfunction in cystic fibrosis airway epithelia
Dana C Borcherding1, Matthew E Siefert1, Songbai Lin1,2
1Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Abstract:
Cystic Fibrosis (CF) is a multi-organ progressive genetic disease caused by loss of functional cystic fibrosis transmembrane conductance regulator (CFTR) channel. Previously, we identified a significant dysfunction in CF cells and model mice of the transcription factor nuclear-factor-E2-related factor-2 (Nrf2), a major regulator of redox balance and inflammatory signaling. Here we report that approved F508del CFTR correctors VX809/VX661 recover diminished Nrf2 function and colocalization with CFTR in CF human primary bronchial epithelia by proximity ligation assay, immunoprecipitation, and immunofluorescence, concordant with CFTR correction. F508del CFTR correctors induced Nrf2 nuclear translocation, Nrf2-dependent luciferase activity, and transcriptional activation of target genes. Rescue of Nrf2 function by VX809/VX661 was dependent on significant correction of F508del and was blocked by inhibition of corrected channel function, or high-level shRNA knockdown of CFTR or F508del-CFTR. Mechanistically, F508del-CFTR modulation restored Nrf2 phosphorylation and its interaction with the coactivator CBP. Our findings demonstrate that sufficient modulation of F508del CFTR function corrects Nrf2 dysfunction in CF.
Insights
Cystic Fibrosis (CF) drug VX809/VX661 restores nuclear-factor-E2-related factor-2 (Nrf2) function in CF cells. This correction is linked to improved cystic fibrosis transmembrane conductance regulator (CFTR) function, highlighting a new therapeutic target.
Area of Science:
- Cell Biology
- Genetics
- Molecular Medicine
Background:
- Cystic Fibrosis (CF) is a genetic disorder caused by dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein.
- Nuclear-factor-E2-related factor-2 (Nrf2), a key regulator of cellular defense mechanisms, is impaired in CF.
Purpose of the Study:
- To investigate if CFTR correctors can restore Nrf2 function in CF.
- To elucidate the mechanism by which CFTR correctors impact Nrf2 activity.
Main Methods:
- Proximity ligation assay, immunoprecipitation, and immunofluorescence were used to assess Nrf2 and CFTR colocalization.
- Nrf2-dependent reporter gene assays and target gene expression analysis were performed.
- Experiments involved primary human bronchial epithelial cells from CF patients and CFTR knockdown models.
Main Results:
- CFTR correctors VX809/VX661 restored Nrf2 function and its colocalization with CFTR in CF cells.
- These correctors promoted Nrf2 nuclear translocation and transcriptional activity.
- Nrf2 rescue was dependent on CFTR correction and functional channel activity.
Conclusions:
- Modulation of F508del-CFTR function by approved correctors can restore Nrf2 dysfunction in Cystic Fibrosis.
- This suggests a direct link between CFTR function and redox/inflammatory signaling pathways regulated by Nrf2.
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...
FDA Approved Drugs: Changes to Approved Drugs
Suctioning the Oropharyngeal Airway
After assembling the equipment, the nurse should practice hand hygiene and don appropriate PPE according to infection control guidelines to avoid the...
Suctioning the Nasopharyngeal Airway
Equipment Required
Cardiopulmonary Resuscitation II: ACLS Airway Management

